Cancer. Targeting bacteria to improve cancer therapy.
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Anand G
AG
Patel
Scott H
SH
Kaufmann
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D001419:Bacteria / Q000187:drug effects / Q000201:enzymology; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000633:toxicity; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D005966:Glucuronidase / Q000037:antagonists & inhibitors*; D007413:Intestinal Mucosa / Q000187:drug effects / Q000378:metabolism / Q000382:microbiology*; D000077146:Irinotecan; D051379:Mice
D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; C106003:SN38-Glu; D000077146:Irinotecan; D005966:Glucuronidase; D002166:Camptothecin